What is Sermorelin Peptide?
Sermorelin is among the growth hormone releasing hormone (GHRH) analogs developed in recent years. It aims to maintain the positive effects of natural GHRH and overcome the adverse outcome of GHRH. Sermorelin (Geref) is used clinically to assess growth hormone secretion, but the peptide is of additional interest for its abilities to:
– Decrease tissue scarring after the cardiac attack.
– Improve bone density.
– Enhance nutrition in chronic illness.
– Improve renal function.
– Combat the effects of dementia.
– Reduce seizure activity.
Molecular Formula: C149H246N44O42S
Molecular Weight: 3357.9 g/mol
PubChem: CID 16129620
CAS Number: 86168-78-7
Sermorelin and Cardiac Health
Cardiac attack, apart from being fatal, can also cause long-term disability secondary to cardiac failure, cardiac conduction abnormalities (arrhythmias), decreased exercise capacity, pain, and more. A number of these issues arise from cardiac remodeling due to damaged myocytes (heart muscle cells). Often, it leads not only to scarring of tissue in the area of damage following a cardiac attack but extends to surrounding healthy tissues as well. Cardiac remodeling leads to long-term problems, and prevention helps to improve outcomes both immediately after a heart attack and years down the line.
In 2016, a study in pigs showed that sermorelin use helps to reduce the remodeling after a cardiac attack. The research showed that sermorelin:
– Decreases cell death in cardiomyocytes.
– Improves the production of extracellular matrix components needed for adequate healing.
– Promotes angiogenesis to damaged tissue.
– Reduces the production of pro-inflammatory substances.
Clinically, it enhances diastolic function, decreases scar size, and increases capillary growth. It is being explored for different cardiac diseases like a cardiac failure and valve disorders.
Gamma-aminobutyric acid (GABA) is a central nervous system signaling molecule that decreases electrical activity in the spinal cord and reduces overall electrical excitability in the central nervous system. Many anti-seizure medications work either to, enhance levels of GABA in the central nervous system or mimic GABA by binding to GABA. In a recent murine model with epilepsy, scientists administered sermorelin to study the effect on seizure activity. GHRH analogs were observed to activate GABA receptors and inhibit seizures. This will open avenues for new drugs as the existing ones have adverse effects.
3. Sermorelin and Sleep
Orexin is a powerful neurochemical secreted by certain neurons in the brain. It has been observed to regulate sleep cycles. Growth and healing of the body by the growth hormone secretion happen maximally during sleep. Studies have found that a functional GHRH axis is required for orexin production and function. In addition, exogenous administration of sermorelin and other GHRH agonists enhances orexin secretion. Sermorelin is being studied to improve sleep disorders.
4. Sermorelin Peptide is Preferred to Growth Hormone
Sermorelin is a growth hormone-releasing hormone derivative that mediates the beneficial effects of GH but not its side effects. Sermorelin is used to increase GH levels in humans over direct use of the hormone itself as the peptide can be regulated through physiological feedback mechanisms that prevent side effects of GH. The adverse effects include overdose, improper dosing, and unintended side effects like edema, joint pain, and dysregulation of normal physiology.
A second reason for sermorelin preference is that it is not subject to tachyphylaxis, the process by which the body becomes acclimatized to a medication dose and requires higher doses to achieve desired effects. In certain cases, tachyphylaxis is so aggravated that a drug holiday (complete stoppage of drug use) is essential to regain the effects of medication. Studies have shown that the body has a unique response to the long-term administration of sermorelin. The body enhances the production of GHRH receptors instead of downregulating them. This prevents the onset of tachyphylaxis and thus the effect of sermorelin is maintained without increasing its dose.
The peptide exhibits moderate side effects, low oral bioavailability, and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not match up to human requirements.